JP2018529749A - ペプチド薬物を経口送達するための医薬製剤 - Google Patents

ペプチド薬物を経口送達するための医薬製剤 Download PDF

Info

Publication number
JP2018529749A
JP2018529749A JP2018517702A JP2018517702A JP2018529749A JP 2018529749 A JP2018529749 A JP 2018529749A JP 2018517702 A JP2018517702 A JP 2018517702A JP 2018517702 A JP2018517702 A JP 2018517702A JP 2018529749 A JP2018529749 A JP 2018529749A
Authority
JP
Japan
Prior art keywords
sodium
complex
iron
salt
copper
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018517702A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018529749A5 (cg-RX-API-DMAC7.html
Inventor
フロリアン・フェーガー
マルティン・ヴェルレ
Original Assignee
シプルメット・ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シプルメット・ゲーエムベーハー filed Critical シプルメット・ゲーエムベーハー
Publication of JP2018529749A publication Critical patent/JP2018529749A/ja
Publication of JP2018529749A5 publication Critical patent/JP2018529749A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2018517702A 2015-10-07 2016-10-07 ペプチド薬物を経口送達するための医薬製剤 Pending JP2018529749A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15188838 2015-10-07
EP15188838.5 2015-10-07
PCT/EP2016/074110 WO2017060500A1 (en) 2015-10-07 2016-10-07 Pharmaceutical formulations for the oral delivery of peptide drugs

Publications (2)

Publication Number Publication Date
JP2018529749A true JP2018529749A (ja) 2018-10-11
JP2018529749A5 JP2018529749A5 (cg-RX-API-DMAC7.html) 2019-11-14

Family

ID=54292636

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018517702A Pending JP2018529749A (ja) 2015-10-07 2016-10-07 ペプチド薬物を経口送達するための医薬製剤

Country Status (8)

Country Link
US (1) US10905744B2 (cg-RX-API-DMAC7.html)
EP (1) EP3359181A1 (cg-RX-API-DMAC7.html)
JP (1) JP2018529749A (cg-RX-API-DMAC7.html)
CN (1) CN108135962A (cg-RX-API-DMAC7.html)
AU (1) AU2016335287A1 (cg-RX-API-DMAC7.html)
CA (1) CA2997343A1 (cg-RX-API-DMAC7.html)
IL (1) IL258464A (cg-RX-API-DMAC7.html)
WO (1) WO2017060500A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020529467A (ja) * 2018-02-02 2020-10-08 ノヴォ ノルディスク アー/エス Glp−1アゴニスト、n−(8−(2−ヒドロキシベンゾイル)アミノ)カプリル酸の塩及び滑沢剤を含む固形組成物

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
AU2012241894B2 (en) 2011-04-12 2015-12-03 Novo Nordisk A/S Double-acylated GLP-1 derivatives
ES2715308T3 (es) 2012-03-22 2019-06-03 Novo Nordisk As Composiciones que comprenden un agente de suministro y su preparación
KR102072202B1 (ko) 2012-03-22 2020-01-31 노보 노르디스크 에이/에스 Glp-1 펩티드의 조성물 및 그것의 제조
WO2013189988A1 (en) 2012-06-20 2013-12-27 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
RS58039B1 (sr) 2013-05-02 2019-02-28 Novo Nordisk As Oralno doziranje glp-1 jedinjenja
HRP20211127T1 (hr) * 2015-10-09 2021-10-15 Radius Health, Inc. Formulacije analoga pthrp, njihovi transdermalni flasteri, i njihova uporaba
ES2904891T3 (es) 2016-04-18 2022-04-06 Radius Health Inc Formulaciones de abaloparatida, parche transdérmico de la misma y usos de la misma
CN109381695A (zh) * 2017-08-09 2019-02-26 武汉武药科技有限公司 一种门冬氨酸帕瑞肽注射液及其制备方法和用途
TWI751379B (zh) * 2017-09-21 2022-01-01 奧孟亞股份有限公司 用於遞送胜肽之藥物組合物
US20210087250A1 (en) * 2018-04-06 2021-03-25 Cyprumed Gmbh Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
CA3102509A1 (en) * 2018-06-10 2019-12-19 Zim Laboratories Limited Oral mucosal delivery systems comprising monophasic concentrate of teriparatide
GB201813678D0 (en) * 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
JP7480132B2 (ja) * 2018-10-12 2024-05-09 アドヴァンスド アクセラレーター アプリケーションズ インターナショナル エセ.アー. 放射性標識されたgprpアンタゴニスト及び界面活性剤を含む医薬組成物
WO2020180534A1 (en) 2019-03-01 2020-09-10 President And Fellows Of Harvard College Methods and compositions for protein delivery
WO2020183318A1 (en) * 2019-03-08 2020-09-17 Anya Biopharm Inc. Oral formulation and treatment of pth analog.
CN111714643A (zh) * 2019-03-22 2020-09-29 约翰霍普金斯大学 一种单宁酸/Fe3+纳米颗粒体系、药物递送方法
GB201906917D0 (en) * 2019-05-16 2019-07-03 Intract Pharma Ltd Novel compositions
CN112057619A (zh) * 2019-06-10 2020-12-11 苏州兰鼎生物制药有限公司 一种具有降血糖作用的药物组合物
CN115209910A (zh) * 2020-03-18 2022-10-18 四川海思科制药有限公司 口服药物组合物
US20210315930A1 (en) * 2020-04-14 2021-10-14 David A. Cuddeback Nutraceutical composition for multimodal prophylaxis against and treatment of viral and bacterial infection and inflammation
CN114272511B (zh) * 2021-01-12 2023-08-01 广州新济药业科技有限公司 司美格鲁肽可溶性微针贴片及其制备方法
FR3120189B1 (fr) 2021-03-01 2024-11-29 Farid Bennis Composition pharmaceutique pour une administration par voie orale d’un agoniste du récepteur du GLP-1
CN113117050B (zh) * 2021-05-06 2022-04-26 合肥天汇孵化科技有限公司 多肽组合物及其用途
CA3237751A1 (en) 2021-11-10 2023-05-19 Tyler Brown Ionic liquid compositions
WO2024043867A1 (en) * 2022-08-20 2024-02-29 Sinapu Llc C60 histidine carnosine fumarates and use
CN115321657B (zh) * 2022-08-31 2023-10-03 四川农业大学 一种疏水壳聚糖-聚合氯化铝Hmcs-PAC复合絮凝剂及其制备与应用
WO2024077409A1 (en) * 2022-10-09 2024-04-18 Guangzhou Dazhou Biomedicine Ltd. Oral delivery of therapeutic agents
US20260007869A1 (en) 2023-06-23 2026-01-08 Vaxess Technologies, Inc. Microneedle array patches (maps), systems, and methods for manufacturing and using same
WO2025046590A1 (en) * 2023-08-30 2025-03-06 Entera Bio Ltd. Formulations for oral administration of active agents
US12377156B2 (en) * 2023-10-24 2025-08-05 Neuvian Ip Holdings, Llc Compositions and methods for treatment of wounds and inflammatory skin conditions
US20250235509A1 (en) * 2024-01-23 2025-07-24 Men Hwei Tsai Formulation and Method of Preparing Glucagon-like Peptide-1 (GLP-1) for Oral Administration
WO2025188317A1 (en) * 2024-03-08 2025-09-12 Neuvian Skincare Llc Compositions and methods for hair treatment
US12409204B1 (en) 2024-03-08 2025-09-09 Neuvian Ip Holdings, Llc Compositions and methods for hair treatment
CN122376711A (zh) * 2024-06-03 2026-07-14 深圳奥礼生物科技有限公司 口服的多肽组合物
CN122251618A (zh) * 2026-05-27 2026-06-23 浙江大学 一种钙离子或硼酸酯键桥联的阳离子基多肽口服递送系统

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998009645A1 (en) * 1996-09-04 1998-03-12 Dott Research Laboratory Peptide-containing drug compositions for oral administration
US6248360B1 (en) * 2000-06-21 2001-06-19 International Health Management Associates, Inc. Complexes to improve oral absorption of poorly absorbable antibiotics
JP2006028031A (ja) * 2004-07-12 2006-02-02 Ltt Bio-Pharma Co Ltd 経粘膜吸収用薬物封入ナノ粒子
JP2013501071A (ja) * 2009-08-06 2013-01-10 アイロンウッド ファーマシューティカルズ, インコーポレイテッド リナクロチドを含む処方物

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
US5661130A (en) 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
EP1060191B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Derivatives of glp-1 analogs
AU3247799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
AU2610899A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
DE69916811T2 (de) 1998-02-27 2005-04-14 Novo Nordisk A/S Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden
NZ534409A (en) 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
BR0107764A (pt) 2000-01-20 2002-11-12 Basilea Pharmaceutica Ag Composições de peptìdeo cìclico nasalmente administráveis
WO2003007913A2 (en) 2001-07-20 2003-01-30 Samir Mitragotri Method for oral drug delivery
IL161446A0 (en) 2001-11-26 2004-09-27 Daiichi Suntory Pharma Co Ltd Medicinal compositions for nasal absorption
WO2004024225A1 (en) 2002-09-16 2004-03-25 Zicam, Llc. System and method for delivering a composition to the nasal membrane
EP1670515A2 (en) 2003-09-19 2006-06-21 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
CN101665538A (zh) 2003-12-18 2010-03-10 诺沃挪第克公司 与白蛋白样物质相连的新glp-1类似物
JP2007537141A (ja) 2003-12-18 2007-12-20 ノボ ノルディスク アクティーゼルスカブ 新規なglp−1化合物
WO2005080489A1 (fr) 2004-02-23 2005-09-01 Caiteng Zhang Solution de chelate(s) metal/polymere et leurs utilisations
ES2542228T3 (es) 2004-07-08 2015-08-03 Novo Nordisk A/S Marcas de prolongación polipeptídica que comprenden un resto de tetrazol
CN101027318B (zh) 2004-07-19 2016-05-25 比奥孔有限公司 胰岛素-低聚物共轭物,制剂及其用途
US20060078623A1 (en) 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
CA2578748C (en) 2004-09-03 2014-10-14 Kyowa Hakko Kogyo Co., Ltd. Composition and method for prevention or treatment of stomatitis
JP5107713B2 (ja) 2004-10-07 2012-12-26 ノヴォ ノルディスク アー/エス 遅延性のエキセンディン−4化合物
JP2008515856A (ja) 2004-10-07 2008-05-15 ノボ ノルディスク アクティーゼルスカブ 遅延性glp−1化合物
ES2484796T3 (es) 2005-03-18 2014-08-12 Novo Nordisk A/S Compuestos de GLP-1 extendidos
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
WO2007025332A1 (en) 2005-08-29 2007-03-08 Dia-B Tech Limited A peptide and zinc ion composition for treating diabetes and enhancing immune function
EP2722054B1 (en) 2005-09-06 2018-03-21 Oramed Pharmaceuticals Inc. Methods and compositions for oral administration of proteins
US20070086952A1 (en) 2005-09-29 2007-04-19 Biodel, Inc. Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
US20090214657A1 (en) 2005-11-30 2009-08-27 Muhammad Waseem Tahir Qazi Orally Absorbed Pharmaceutical Formulation and Method of Administration
US20090318353A1 (en) 2006-08-25 2009-12-24 Novo Nordisk A/S Acylated Exendin-4 Compounds
US20100261637A1 (en) 2007-09-05 2010-10-14 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
US20100292133A1 (en) 2007-09-05 2010-11-18 Novo Nordisk A/S Truncated glp-1 derivaties and their therapeutical use
EP2190872B1 (en) 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
RS60101B1 (sr) 2008-08-15 2020-05-29 Ironwood Pharmaceuticals Inc Formulacije koje sadrže linaklotid za oralnu primenu
AU2010250452B2 (en) 2009-05-20 2014-06-05 Toray Industries, Inc. Cell membrane-permeable peptides
WO2011019819A1 (en) 2009-08-12 2011-02-17 Forest Laboratories Holdings Limited Orally disintegrating compositions of linaclotide
CN102596253B (zh) 2009-09-30 2013-11-06 蒂奥迈里克斯研究与指导有限公司 含有维生素b 亚结构的粘膜粘着聚合物
WO2011116139A2 (en) 2010-03-16 2011-09-22 Chiasma Inc. Improved pharmaceutical compositions and methods of delivery
KR20130100897A (ko) 2010-04-21 2013-09-12 나노메가 메디컬 코포레이션 나노입자의 약제학적 조성물
WO2012112319A1 (en) 2011-02-04 2012-08-23 Aegis Therapeutics, Llc Orally bioavailable peptide drug compositions and methods thereof
CN103458873B (zh) 2011-04-14 2016-04-13 诺沃—诺迪斯克有限公司 用于口服肽递送的脂肪酸酰化的氨基酸
WO2012170828A1 (en) 2011-06-10 2012-12-13 Monosol Rx, Llc Combination peptide-nanoparticles and delivery systems incorporating same
US20130004590A1 (en) * 2011-06-28 2013-01-03 Lin Connie B Zinc oxide/acid containing compositions and methods for treating and/or preventing enzymatic irritation
KR102072202B1 (ko) 2012-03-22 2020-01-31 노보 노르디스크 에이/에스 Glp-1 펩티드의 조성물 및 그것의 제조
CA2872314C (en) 2012-05-03 2021-08-31 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
US20150174076A1 (en) 2012-06-14 2015-06-25 Entrega, Inc. Mucoadhesive devices for delivery of active agents
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重glp-1/升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
JP2017525656A (ja) 2014-06-04 2017-09-07 ノヴォ ノルディスク アー/エス 医療用のglp−1/グルカゴン受容体コアゴニスト
DK3006045T3 (en) * 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998009645A1 (en) * 1996-09-04 1998-03-12 Dott Research Laboratory Peptide-containing drug compositions for oral administration
US6248360B1 (en) * 2000-06-21 2001-06-19 International Health Management Associates, Inc. Complexes to improve oral absorption of poorly absorbable antibiotics
JP2006028031A (ja) * 2004-07-12 2006-02-02 Ltt Bio-Pharma Co Ltd 経粘膜吸収用薬物封入ナノ粒子
JP2013501071A (ja) * 2009-08-06 2013-01-10 アイロンウッド ファーマシューティカルズ, インコーポレイテッド リナクロチドを含む処方物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CLIN. PHARMACOL. THER. (2009) VOL.86, NO.6, P.644-650, JPN6020031995, ISSN: 0004472598 *
REACT. FUNCT. POLYM. (2011) VOL.71, ISSUE 2, P.280-287, JPN6020031996, ISSN: 0004472599 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020529467A (ja) * 2018-02-02 2020-10-08 ノヴォ ノルディスク アー/エス Glp−1アゴニスト、n−(8−(2−ヒドロキシベンゾイル)アミノ)カプリル酸の塩及び滑沢剤を含む固形組成物
JP2021105014A (ja) * 2018-02-02 2021-07-26 ノヴォ ノルディスク アー/エス Glp−1アゴニスト、n−(8−(2−ヒドロキシベンゾイル)アミノ)カプリル酸の塩及び滑沢剤を含む固形組成物
JP7494141B2 (ja) 2018-02-02 2024-06-03 ノヴォ ノルディスク アー/エス Glp-1アゴニスト、n-(8-(2-ヒドロキシベンゾイル)アミノ)カプリル酸の塩及び滑沢剤を含む固形組成物
JP2024102371A (ja) * 2018-02-02 2024-07-30 ノヴォ ノルディスク アー/エス Glp-1アゴニスト、n-(8-(2-ヒドロキシベンゾイル)アミノ)カプリル酸の塩及び滑沢剤を含む固形組成物

Also Published As

Publication number Publication date
CN108135962A (zh) 2018-06-08
IL258464A (en) 2018-05-31
US20180280481A1 (en) 2018-10-04
AU2016335287A1 (en) 2018-04-12
US10905744B2 (en) 2021-02-02
CA2997343A1 (en) 2017-04-13
EP3359181A1 (en) 2018-08-15
WO2017060500A1 (en) 2017-04-13

Similar Documents

Publication Publication Date Title
US10905744B2 (en) Pharmaceutical formulations for the oral delivery of peptide drugs
EP3204045B1 (en) Pharmaceutical formulations for the oral delivery of peptide or protein drugs
JP7744049B2 (ja) 治療用ペプチド及び治療用タンパク質の経粘膜送達のための薬学的組成物
ES2541309T3 (es) Productos farmacéuticos peptídicos orales de acción rápida
WO2018065634A1 (en) Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
JP6910950B2 (ja) 固形経口剤形
US20240041983A1 (en) Improved pharmaceutical formulations of glp-1 receptor agonists
JP2024111060A (ja) ペプチド送達のための医薬組成物
CN118267455A (zh) 胰高血糖素样肽2(glp-2)类似物的制剂
AU2010323117B2 (en) Mucosal delivery compositions comprising a peptide complexed with a crown comppound and/or a counter ion
EP4262745B1 (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
US20240299552A1 (en) Pharmaceutical Composition of GLP-1/GLP-2 Dual Agonists
CN119486752A (zh) 包含肽或蛋白和酰化氨基酸的组合物
JP2024509829A (ja) Glp-1受容体作動薬を経口投与するための医薬組成物
HK40095698B (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
HK40095698A (en) Pharmaceutical composition of glp-1/glp-2 dual agonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191004

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191004

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200831

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210329